查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967623

表皮生长因子受体非小细胞肺癌市场－全球产业规模、份额、趋势、机会、预测：按药物类型、通路、地区和竞争格局划分，2021-2031年

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel,By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球表皮生长因子受体 (EGFR) 阳性非小细胞肺癌市场预计将从 2025 年的 2.1458 亿美元成长到 2031 年的 3.2638 亿美元，复合年增长率为 7.24%。

此领域包含旨在抑制 EGFR 蛋白的标靶治疗，EGFR 蛋白是携带特定基因突变患者肿瘤生长的主要驱动因素。市场成长主要受精准肿瘤学应用日益广泛以及分子诊断融入标准治疗的推动。根据 2024 年国际肺癌研究协会 (IASLC) 的数据，67% 的受访者估计其所在地区超过一半的肺癌患者目前正在接受生物标记检测，这一趋势透过识别需要此类检测的患者群体，正在提升市场潜力。

市场概览
预测期 2027-2031
市场规模：2025年 2.1458亿美元
市场规模：2031年 3.2638亿美元
复合年增长率：2026-2031年 7.24%
成长最快的细分市场 Erlotinib
最大的市场 北美洲

然而，新一代疗法的高成本构成了市场准入的重大障碍。先进的蛋白酪氨酸激酶抑制剂价格高昂，往往超出发展中国家医疗体系的报销限额，限制了经济敏感地区病患的用药机会。这种经济障碍严重阻碍了中低收入国家市场的扩充性，进而限制了这些标准疗法在全球的推广和应用。

市场驱动因素

全球非小细胞肺癌发生率的上升是市场成长的主要驱动力，也使得大规模治疗方案的需求变得特别迫切。随着患者数量的增加，医疗系统必须优先保障标靶表皮生长因子受体抑制剂的供应，以有效控制肿瘤进展。根据美国癌症协会发布的《2024年癌症事实与数据》报告，预计光是2024年美国就将新增约234,580例肺癌和支气管癌病例。日益加重的疾病负担将直接推动对分子标靶疗法的需求成长，并随着诊断通讯协定的改进，更多符合标准治疗条件的患者涌入市场，从而促进商业性扩张。

同时，新一代蛋白酪氨酸激酶抑制剂的快速发展正在克服突变阳性患者获得性抗药性的挑战。製药公司正积极加强其临床研发管线，以证明第三代药物在可切除和转移性疾病中的卓越疗效。例如，Astra Zeneca在2024年6月发布的新闻稿中公布了LAURA III期临床试验的结果，强调泰瑞沙（Tagrisso）与安慰剂相比，显着降低了不可切除的III期EGFR突变阳性非小细胞肺癌（NSCLC）患者的疾病进展或死亡风险达84%。这项成功凸显了这些治疗方法的经济价值，并进一步证明了先进治疗方法的广泛市场应用，正如Astra Zeneca2024年报告所显示，其旗舰抑制剂的收入已达58亿美元。

市场挑战

新一代疗法的高昂成本是全球表皮生长因子受体阳性非小细胞肺癌市场成长的主要障碍。先进的蛋白酪氨酸激酶抑制剂价格仍然昂贵，往往超出医疗系统的报销能力，尤其是在对成本高度敏感的经济体中。这种经济差距实际上阻碍了中低收入国家大量合格的患者获得这些必要的治疗，从而严重阻碍了市场扩张，并最终限制了这些标靶治疗在全球范围内的商业性化应用。

此外，这种经济压力直接阻碍了市场发展所需的临床通讯协定的采纳。根据国际肺癌研究协会 (IASLC) 2024 年的一项全球调查，27.2% 的医疗专业人员认为成本是实施最佳生物标记驱动医疗的主要障碍。这项数据凸显了资金限制如何直接阻碍市场渗透，因为治疗体系相关的高成本阻碍了精准肿瘤学在全球有效惠及病患。

市场趋势

联合治疗作为第一线治疗方案，正逐渐成为治疗常见EGFR突变患者的变革性标准，将治疗模式从单一治疗转向更积极的多药物联合治疗。这种转变旨在透过在诊断后立即针对共存的致癌性路径来延缓抗药性的产生并延长生存期，其中无需化疗的双特异性抗体联合治疗尤其具有前景。例如，强生公司在其2025年3月发布的III期MARIPOSA试验新闻稿中报告称，Rybrevant和Lazcluze联合治疗在3.5年时达到了56%的生存率。这比现有标准治疗（单药治疗）的44%存活率有了显着提高。

此外，在蛋白酪氨酸激酶抑制剂（TKI）治疗中越来越多地使用抗体药物复合体（ADC）可以满足初始标靶治疗后疾病进展患者的重大未满足需求。鑑于抗药性机制不可避免地出现，ADC 透过将细胞毒性有效载荷递送至表达特定表面抗原（如 TROP2 和 HER3）的癌细胞，有效绕过耗竭的激酶抑制通路，从而提供了一种强有力的挽救性治疗选择。根据发表于 2025 年 1 月《应用临床试验》（Applied Clinical Trials）杂誌上的报导，在非鳞状非小细胞肺癌患者中，与多西他赛相比，达托泊单抗德鲁替康可使疾病进展或死亡风险降低 37%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：表皮生长因子受体在非小细胞肺癌的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物类型（Erlotinib、Afatinib、Gefitinib、Osimertinib、Dacomitinib）
    • 分销通路（线上、线下）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美表皮生长因子受体非小细胞肺癌市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲表皮生长因子受体非小细胞肺癌市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区表皮生长因子受体非小细胞肺癌市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲非小细胞肺癌表皮生长因子受体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲非小细胞肺癌表皮生长因子受体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球表皮生长因子受体非小细胞肺癌市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Genentech, Inc.
  • Astellas Pharma Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 20183

The Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market is projected to increase from USD 214.58 Million in 2025 to USD 326.38 Million by 2031, expanding at a CAGR of 7.24%. This sector consists of specialized targeted therapies aimed at inhibiting the EGFR protein, a key driver of tumor growth in patients with specific genetic mutations. Market growth is primarily fueled by the increasing use of precision oncology and the integration of molecular diagnostics into standard care. Data from the International Association for the Study of Lung Cancer in 2024 revealed that 67% of survey respondents estimated over half of lung cancer patients in their regions are now undergoing biomarker testing, a trend that boosts market potential by identifying the necessary patient pool.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 214.58 MIllion
Market Size 2031USD 326.38 MIllion
CAGR 2026-20317.24%
Fastest Growing SegmentErlotinib
Largest MarketNorth America

However, the market faces a substantial obstacle due to the high costs associated with next-generation therapeutic agents. The steep pricing of advanced tyrosine kinase inhibitors often surpasses reimbursement limits within developing healthcare systems, restricting patient access in economically sensitive regions. This financial barrier significantly hinders market scalability in low- and middle-income nations, thereby limiting the global distribution and adoption of these standard-of-care treatments.

Market Driver

The increasing global incidence of Non-Small Cell Lung Cancer serves as a major driver for market growth, creating a critical need for scalable therapeutic solutions. As patient numbers rise, healthcare systems must prioritize acquiring targeted epidermal growth factor receptor inhibitors to effectively manage tumor progression. The American Cancer Society's 'Cancer Facts & Figures 2024' report projected approximately 234,580 new diagnoses of lung and bronchus cancer in the United States alone for that year. This growing disease burden directly necessitates a higher volume of molecularly targeted agents, sustaining commercial expansion as improved diagnostic protocols identify more candidates eligible for standard treatments.

Concurrently, the rapid advancement of next-generation tyrosine kinase inhibitors is overcoming the challenge of acquired drug resistance in mutation-positive patients. Pharmaceutical companies are actively enhancing clinical pipelines to prove the superior efficacy of third-generation agents in both resectable and metastatic scenarios. For instance, AstraZeneca's June 2024 press release regarding the 'LAURA Phase III Trial Results' highlighted that Tagrisso significantly reduced the risk of disease progression or death by 84% compared to a placebo in unresectable Stage III EGFR-mutated NSCLC. This success underlines the economic value of these therapies, further evidenced by AstraZeneca's 2024 report citing $5.8 billion in revenue from its flagship inhibitor, demonstrating the widespread market adoption of advanced biological treatments.

Market Challenge

The exorbitant cost of next-generation therapeutic agents represents a major hurdle limiting the growth of the Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market. Advanced tyrosine kinase inhibitors maintain high price points that often outstrip the reimbursement capacities of healthcare systems, especially within cost-sensitive economies. This financial gap creates a significant barrier to market scalability by effectively preventing a large portion of eligible patients in low- and middle-income countries from accessing these essential treatments, thereby restricting the global commercial reach of such targeted interventions.

Furthermore, this economic pressure directly impedes the adoption of clinical protocols necessary for market development. According to a 2024 global survey by the International Association for the Study of Lung Cancer, 27.2% of healthcare professionals cited cost as the main impediment to implementing optimal biomarker-driven care. This statistic highlights how financial constraints directly obstruct market penetration, as the high costs associated with the treatment ecosystem hinder the effective delivery of precision oncology to patients on a global scale.

Market Trends

First-line combination therapies are emerging as a transformative standard for treating patients with common EGFR mutations, moving the paradigm from monotherapy toward more aggressive multi-agent regimens. This shift aims to delay resistance and prolong survival by targeting concurrent oncogenic pathways immediately upon diagnosis, with chemotherapy-free bispecific antibody combinations showing particular promise. For example, Johnson & Johnson reported in a March 2025 press release for the 'Phase III MARIPOSA Trial' that the combination of Rybrevant and Lazcluze resulted in a 56% survival rate at 3.5 years, compared to 44% for patients treated with the existing standard-of-care monotherapy.

Additionally, the increasing use of antibody-drug conjugates (ADCs) in post-TKI settings is addressing significant unmet needs for patients whose disease progresses following initial targeted therapy. As resistance mechanisms inevitably arise, ADCs provide a potent salvage option by delivering cytotoxic payloads to tumor cells expressing specific surface antigens like TROP2 or HER3, effectively bypassing exhausted kinase inhibition pathways. According to a January 2025 article in Applied Clinical Trials regarding the 'TROPION-Lung05 and TROPION-Lung01 Trials,' datopotamab deruxtecan reduced the risk of disease progression or death by 37% in non-squamous non-small cell lung cancer patients compared to docetaxel.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Genentech, Inc.
  • Astellas Pharma Inc

Report Scope

In this report, the Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market, By Drug Type

  • Erlotinib
  • Afatinib
  • Gefitinib
  • Osimertinib
  • Dacomitinib

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market, By Distribution Channel

  • Online
  • Offline

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market.

Available Customizations:

Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Erlotinib, Afatinib, Gefitinib, Osimertinib, Dacomitinib)
    • 5.2.2. By Distribution Channel (Online, Offline)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. AstraZeneca plc.
  • 15.4. Pfizer Inc.
  • 15.5. Novartis AG
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Takeda Pharmaceutical Company Limited
  • 15.8. AbbVie Inc.
  • 15.9. Genentech, Inc.
  • 15.10. Astellas Pharma Inc

16. Strategic Recommendations

17. About Us & Disclaimer